New hope for esophageal cancer: trial tests powerful drug combo to shrink tumors before surgery
NCT ID NCT07263919
Summary
This study is testing whether adding a new immunotherapy drug called cadonilimab to standard chemotherapy, given both before and after surgery, works better than chemotherapy alone for patients with a type of esophageal cancer that can be surgically removed. The goal is to see if this combination helps shrink or eliminate the tumor more effectively before surgery and prevents the cancer from coming back afterward. Researchers will measure how many patients have no cancer left after treatment, how long patients live without the cancer returning, and the safety of the combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE LOCALLY ADVANCED THORACIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Air Force Medical University
RECRUITINGXi'an, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.